Latest Breaking News On - Molecular biotechnology - Page 6 : comparemela.com

J&J: promising results in multiple myeloma -December 13, 2023 at 09:28 am EST

Johnson & Johnson has announced new results from a Phase III study of Carvykti in adults with relapsed lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy ..

Roberto minaDivision of hematologyUniversity of turinHealth sciencesDepartment of molecular biotechnologyAssistant professorMolecular biotechnology

Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with E

Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with E
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesHemophagocytic lymphohistiocytosisRoberto minaSatu glawePrnewswire johnsonDrug administrationDepartment of molecular biotechnologyHealth sciencesUniversity of torinoAmerican society of hematologyEuropean organisation for researchEuropean commissionExchange commissionLegend biotech united states incNone of janssen research developmentClinical development cellular therapy program

Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma

Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesRoberto minaPrnewswire johnsonSatu glaweHemophagocytic lymphohistiocytosisNone of janssen research developmentUniversity of torinoDivision of hematologyDrug administrationClinical development cellular therapy programJanssen research developmentJanssen biotech incEuropean organisation for researchAmerican society of hematologyAmerican society of clinical oncologyLegend biotech united states inc

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J. (BUSINESS WIRE) Dec 11, 2023

United statesNew jerseyRoberto minaCiltacabtagene autoleucelYing huangJessie yeungAlexandra venturaAmerican cancer societyExchange commission onLegend biotech corporationAmerican society of hematology annual meetingClinical developmentEuropean organisation for researchJanssen biotech incDivision of hematologyUniversity of torino

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in He

In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of careThe as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall responseLonger-term data from CARTITUDE-2 showed deep and durable respons.

United statesYing huangAlexandra venturaJessie yeungRoberto minaUniversity of torinoCorporate communications investor relationsDepartment of molecular biotechnologyClinical developmentHealth sciencesEuropean organisation for researchAmerican society of hematologyDivision of hematologyJanssen biotech incLegend biotech corporationLegend biotech